Coeptis Therapeutics Faces Delisting Notice
Ticker: COEPW · Form: 8-K · Filed: Sep 19, 2024 · CIK: 1759186
| Field | Detail |
|---|---|
| Company | Coeptis Therapeutics Holdings, INC. (COEPW) |
| Form Type | 8-K |
| Filed Date | Sep 19, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $11.50, $1.00, $5,000,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Coeptis got a delisting warning, stock might be in trouble.
AI Summary
Coeptis Therapeutics Holdings, Inc. filed an 8-K on September 19, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The company was formerly known as Bull Horn Holdings Corp. and changed its name on November 15, 2018. The filing also includes other events and financial statements/exhibits.
Why It Matters
This filing indicates potential delisting from a stock exchange, which could significantly impact the liquidity and trading of Coeptis Therapeutics' stock.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.
Key Players & Entities
- Coeptis Therapeutics Holdings, Inc. (company) — Registrant
- Bull Horn Holdings Corp. (company) — Former company name
- September 17, 2024 (date) — Date of earliest event reported
- September 19, 2024 (date) — Filing date
- November 15, 2018 (date) — Date of name change
FAQ
What specific listing rule or standard has Coeptis Therapeutics Holdings, Inc. failed to satisfy?
The filing does not specify the exact listing rule or standard that Coeptis Therapeutics Holdings, Inc. has failed to satisfy, only that a notice has been received.
What is the potential consequence of failing to satisfy the continued listing rule?
The potential consequence is the delisting of the company's securities from the stock exchange.
When was the company formerly known as Bull Horn Holdings Corp.?
The company was formerly known as Bull Horn Holdings Corp. and changed its name on November 15, 2018.
What is the primary business of Coeptis Therapeutics Holdings, Inc.?
Coeptis Therapeutics Holdings, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code 2836.
What is the filing date of this 8-K report?
This 8-K report was filed on September 19, 2024.
Filing Stats: 830 words · 3 min read · ~3 pages · Grade level 12.4 · Accepted 2024-09-19 08:00:09
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share COEP Nasdaq Capital Mark
- $11.50 — e-half of one share of Common Stock for $11.50 per whole share COEPW Nasdaq Capita
- $1.00 — ment to maintain a minimum bid price of $1.00 per share (the "Minimum Bid Price Requi
- $5,000,000 — equity initial listing requirements of $5,000,000 for Nasdaq, as set forth under Nasdaq L
Filing Documents
- coeptis_8k.htm (8-K) — 34KB
- coeptis_ex9901.htm (EX-99.1) — 9KB
- 0001683168-24-006521.txt ( ) — 260KB
- coep-20240917.xsd (EX-101.SCH) — 3KB
- coep-20240917_def.xml (EX-101.DEF) — 26KB
- coep-20240917_lab.xml (EX-101.LAB) — 36KB
- coep-20240917_pre.xml (EX-101.PRE) — 25KB
- coeptis_8k_htm.xml (XML) — 5KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on January 29, 2024, Coeptis Therapeutics Holdings, Inc. (the "Company") received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon the closing bid price of the Company's common stock, par value $0.0001 per share ("Common Stock"), for the last 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share (the "Minimum Bid Price Requirement") for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Original Notice"). At that time, the Company was provided a compliance period of 180 calendar days from the date of the Original Notice, or until July 29, 2024, to regain compliance with the Minimum Bid Price Requirement, pursuant to Nasdaq Listing Rule 5810(c)(3)(A). As previously disclosed, on July 30, 2024, Coeptis received a letter from the Listing Qualifications Staff of Nasdaq indicating that the Company did not regain compliance with the Minimum Bid Price Requirement by July 29, 2024, and it was determined that the Company was not eligible for another 180 calendar-day extension because it did not meet the minimum stockholders' equity initial listing requirements of $5,000,000 for Nasdaq, as set forth under Nasdaq Listing Rule 5505(b). The Company appealed the decision, as previously disclosed. On September 17, 2024, the Company received a letter from Nasdaq advising the Company that the Company has been granted an extension through January 15, 2025, to regain listing compliance. The Notice has no immediate effect on the continued listing status of the Company's Common Stock on The Nasdaq Capital Market, and, therefore, the Company's listing remains fully effective. The Company will continue to monitor the closing bid price of its Common Stoc
01 Other Events
Item 8.01 Other Events On September 19, 2024, the Company issued a press release announcing that the Nasdaq Hearings Panel granted its request for continued listing on Nasdaq through January 15, 2025, subject to the Company demonstrating compliance with Nasdaq Listing Rule 5550(a)(2). A copy of the press release is included with the Current Report on Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No . Description 99.1 Press Release, dated September 19, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Coeptis Therapeutics Holdings, Inc. Date: September 19, 2024 By: /s/ David Mehalick David Mehalick Chief Executive Officer 3